RIMS1 methylation-guided surveillance
1 paper3 findings
- In silico1
Outcomes
3Quality-adjusted life-years
upin silico1
1 study
Quality-adjusted life-years
upin silico1
RIMS1 methylation-guided surveillance increases quality-adjusted life-years in silico.
In silicoJapanese patients with open-type gastric atrophy after Helicobacter pylori eradication; compared with biennial surveillance in the base-case model30 years
Expert review of pharmacoeconomics & outcomes research9 Oct 2026
Routine endoscopy use
downin silico1
1 study
Routine endoscopy use
downin silico1
RIMS1 methylation-guided surveillance decreases routine endoscopy use in silico (40.9% fewer routine endoscopies versus annual surveillance).
In silicoJapanese patients with open-type gastric atrophy after Helicobacter pylori eradication; compared with annual surveillance30 years
Expert review of pharmacoeconomics & outcomes research9 Oct 2026
Incremental net monetary benefit
upin silico1
1 study
Incremental net monetary benefit
upin silico1
RIMS1 methylation-guided surveillance increases incremental net monetary benefit in silico (Incremental NMB US$62.56/person; ICER US$47,021.24/QALY).
In silicoJapanese patients with open-type gastric atrophy after Helicobacter pylori eradication; compared with biennial surveillance in the base-case model30 years
Expert review of pharmacoeconomics & outcomes research9 Oct 2026